PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NTR vs. BMY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NTR and BMY is 0.22, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

NTR vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Nutrien Ltd. (NTR) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

-10.00%0.00%10.00%20.00%30.00%40.00%AugustSeptemberOctoberNovemberDecember2025
4.80%
34.87%
NTR
BMY

Key characteristics

Sharpe Ratio

NTR:

0.39

BMY:

0.64

Sortino Ratio

NTR:

0.78

BMY:

1.21

Omega Ratio

NTR:

1.09

BMY:

1.15

Calmar Ratio

NTR:

0.18

BMY:

0.38

Martin Ratio

NTR:

0.69

BMY:

1.59

Ulcer Index

NTR:

14.95%

BMY:

11.50%

Daily Std Dev

NTR:

26.64%

BMY:

28.42%

Max Drawdown

NTR:

-57.94%

BMY:

-70.62%

Current Drawdown

NTR:

-50.09%

BMY:

-23.68%

Fundamentals

Market Cap

NTR:

$25.54B

BMY:

$114.17B

EPS

NTR:

$1.48

BMY:

-$3.58

PEG Ratio

NTR:

1.03

BMY:

1.94

Total Revenue (TTM)

NTR:

$25.66B

BMY:

$35.96B

Gross Profit (TTM)

NTR:

$7.56B

BMY:

$24.67B

EBITDA (TTM)

NTR:

$4.38B

BMY:

$605.00M

Returns By Period

In the year-to-date period, NTR achieves a 15.35% return, which is significantly higher than BMY's 0.62% return.


NTR

YTD

15.35%

1M

17.22%

6M

4.79%

1Y

4.86%

5Y*

6.39%

10Y*

N/A

BMY

YTD

0.62%

1M

-0.73%

6M

34.87%

1Y

17.95%

5Y*

0.00%

10Y*

2.21%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NTR vs. BMY — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTR
The Risk-Adjusted Performance Rank of NTR is 5454
Overall Rank
The Sharpe Ratio Rank of NTR is 6060
Sharpe Ratio Rank
The Sortino Ratio Rank of NTR is 5353
Sortino Ratio Rank
The Omega Ratio Rank of NTR is 5050
Omega Ratio Rank
The Calmar Ratio Rank of NTR is 5454
Calmar Ratio Rank
The Martin Ratio Rank of NTR is 5454
Martin Ratio Rank

BMY
The Risk-Adjusted Performance Rank of BMY is 6464
Overall Rank
The Sharpe Ratio Rank of BMY is 6868
Sharpe Ratio Rank
The Sortino Ratio Rank of BMY is 6464
Sortino Ratio Rank
The Omega Ratio Rank of BMY is 6262
Omega Ratio Rank
The Calmar Ratio Rank of BMY is 6363
Calmar Ratio Rank
The Martin Ratio Rank of BMY is 6363
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NTR vs. BMY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Nutrien Ltd. (NTR) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NTR, currently valued at 0.39, compared to the broader market-2.000.002.004.000.390.64
The chart of Sortino ratio for NTR, currently valued at 0.78, compared to the broader market-4.00-2.000.002.004.006.000.781.21
The chart of Omega ratio for NTR, currently valued at 1.09, compared to the broader market0.501.001.502.001.091.15
The chart of Calmar ratio for NTR, currently valued at 0.18, compared to the broader market0.002.004.006.000.180.38
The chart of Martin ratio for NTR, currently valued at 0.69, compared to the broader market-10.000.0010.0020.0030.000.691.59
NTR
BMY

The current NTR Sharpe Ratio is 0.39, which is lower than the BMY Sharpe Ratio of 0.64. The chart below compares the historical Sharpe Ratios of NTR and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00AugustSeptemberOctoberNovemberDecember2025
0.39
0.64
NTR
BMY

Dividends

NTR vs. BMY - Dividend Comparison

NTR's dividend yield for the trailing twelve months is around 4.18%, less than BMY's 4.30% yield.


TTM20242023202220212020201920182017201620152014
NTR
Nutrien Ltd.
4.18%4.83%3.76%3.29%3.06%3.74%3.67%3.47%0.00%0.00%0.00%0.00%
BMY
Bristol-Myers Squibb Company
4.30%4.24%4.44%3.00%2.36%3.69%2.55%3.08%2.55%1.95%2.17%2.46%

Drawdowns

NTR vs. BMY - Drawdown Comparison

The maximum NTR drawdown since its inception was -57.94%, smaller than the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for NTR and BMY. For additional features, visit the drawdowns tool.


-60.00%-50.00%-40.00%-30.00%-20.00%AugustSeptemberOctoberNovemberDecember2025
-50.09%
-23.68%
NTR
BMY

Volatility

NTR vs. BMY - Volatility Comparison

Nutrien Ltd. (NTR) has a higher volatility of 9.00% compared to Bristol-Myers Squibb Company (BMY) at 5.82%. This indicates that NTR's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


4.00%6.00%8.00%10.00%12.00%14.00%AugustSeptemberOctoberNovemberDecember2025
9.00%
5.82%
NTR
BMY

Financials

NTR vs. BMY - Financials Comparison

This section allows you to compare key financial metrics between Nutrien Ltd. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab